Browse by category

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to show cardiovascular benefits beyond weight loss, according to several...

Semaglutide has a positive effect on patients with chronic kidney disease and obesity. By decreasing the amount of protein in urine, the...

Expanding access to the new generation of weight-loss medications could prevent more than 40,000 deaths a year in the US, according to a...

A person's genetic background is a key driver for their BMI and therefore is crucial to understanding their risk of obesity, according to...

Women living with overweight and obesity have a higher risk of hypertension and cardiovascular risk factors than women with a standard...

Eli Lilly and Company has announced a strategic collaboration with the UK’s Department of Health and Social Care (DHSC), Department for...

A team of scientists led by Nanyang Technological University Singapore (NTU Singapore) and Hong Kong University (HKU) has found evidence...

The American Society of Nephrology (ASN) has released its inaugural Kidney Health Guidance (KHG) on the Management of Obesity in Persons...

Semaglutide reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established...

Only about half of US employers (52%) say they effectively manage healthcare costs, according to Gallagher's 2024 US Physical & Emotional...